TYBR Health

TYBR Health announced $30M in Series A financing on July 21, 2026. TYBR Health raised a $30 million Series A led by Vensana Capital and Mutual Capital Partners to expand commercial access to its FDA-cleared B3 GEL System.

Round details

The financing includes backing from Vensana Capital, Mutual Capital Partners, Neovate Capital Partners. The company did not publish a valuation with the announcement.

• Round: Series A
• Capital announced: $30M
• Headquarters: Houston, TX

How the company plans to use the capital

TYBR Health will expand commercial access to its FDA-cleared B3 GEL System, broaden its product indications, and run clinical studies evaluating tissue protection during orthopedic surgery.

Why this matters for GTM teams

The round points to investor interest in medical technology aimed at protecting healing tissue after surgery, with commercial expansion and clinical evidence both part of the plan.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: TYBR Health Series A announcement.